Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corn silk (*Stigma maydis*) is a traditional medicinal botanical and agricultural byproduct of maize (*Zea mays* L.) cultivation. It is rich in bioactive compounds including flavonoids, pectic polysaccharides, saponins, and sterols. Traditionally used in Chinese and other folk medicines, it is currently being investigated for its therapeutic potential in metabolic syndrome, hypertension, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Its pharmacological effects are attributed to antioxidant, anti-inflammatory, and lipid-modulating activities, often mediated through the gut-liver axis, modulation of gut microbiota (e.g., *Akkermansia*), and signaling pathways such as PI3K/Akt and NF-κB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corn silk.